

---

# Index

## A

Airway inflammation, 145, 146, 148, 157  
Airway remodeling, 145, 149  
Allergic rhinitis, 93, 152, 153  
Alternative splicing, 7–16, 28  
Alveolar bone, 12, 54, 64–70  
Antibody, 12, 82, 83, 101, 120, 140, 153, 156, 169,  
195–199, 208, 209  
Asthma, 11, 12, 14, 81, 83, 90, 93, 116, 140, 145–157,  
197, 198, 208, 209  
Asthma model, 81, 146–147  
Atopic dermatitis (AD), 11, 83, 90, 93–95  
Atopic keratoconjunctivitis (AKC), 119–120

## B

Biomarker, 16, 39, 79–85, 93, 102, 106, 108, 120,  
121, 132, 140, 141, 148–150, 154, 155, 157,  
195–200, 209  
Biomaterials, 209  
 $\beta$ igh3, 8, 11, 12, 14  
Body mass index (BMI), 154  
Bone injury, 52, 53  
Bone marrow microenvironment, 15, 129, 130, 132  
Bone morphogenetic protein-1 (BMP-1), 4, 8, 12, 24,  
26–29, 44, 65, 100, 106  
Bone regeneration, 15, 46, 49–58, 69  
Bone repair, 43, 49, 51–52, 54, 55, 57, 58, 166  
Bone stem cell, 49, 52, 66, 165, 166  
Breast cancer, 46, 126, 127, 129–132, 167, 171, 172,  
199, 207, 208

## C

Cancer stem cell (CSC), 126, 129, 130, 167, 171–173  
Capsular contraction, 209  
Cardiac ECM, 36–39  
Cardiac regeneration, 38, 39  
Cardiac valves, 37, 100, 177–189, 196  
CCN3, 15, 16, 24, 26–28  
Chronic kidney disease (CKD), 15, 16, 100, 102, 103,  
106–109  
Chronic respiratory disease, 80

Cigarette smoke and chronic obstructive pulmonary  
disease (COPD), 153, 154  
Cis-element, 10  
Collagen cross-linking, 12, 13, 16, 44–46, 50, 81,  
100, 139  
Colorectal cancer (CRC), 126, 197, 208  
Corneal dystrophy, 12, 114, 119, 208  
Cushion elongation, 179–183  
Cushion remodeling, 185–189

## D

Dental tissue, 63–70, 73, 76  
Dental tissue development, 64, 65  
Dermatoses, 94–96  
Developmental hematopoiesis, 170, 196  
Diabetic retinopathy (DR), 114, 115  
Diagnostic marker, 155, V  
DNA aptamer, 197, 199, 207  
Dupilumab, 156

## E

ECM architecture, 44, 45, 65, 67, 164, 165  
Elastin, 13, 14, 23, 43, 51, 185  
EMI domain, 8, 11–14, 23–28, 44, 65, 90, 100, 119,  
165, 186  
Eosinophilic chronic rhinosinusitis (E CRS), 152, 153  
Eosinophil recruitment, 140, 146, 147  
Epiretinal membrane, 114  
Epithelial to mesenchyme transformation, 179  
Extracellular matrix (ECM), 3, 4, 8, 12–14, 23–28,  
36–40, 44–46, 50, 52, 54, 55, 57, 58, 64–67,  
69, 73, 74, 80–82, 90–93, 95, 96, 100, 102,  
105–108, 114, 118, 121, 125, 129, 131–133,  
139, 141, 164–166, 168–171, 173, 178–181,  
183, 185, 187, 188, 196–200

## F

Fas1 domains, 7–9, 11, 12, 14, 25, 100, 165  
Fetal protein, 65  
Fibrillogenesis, 3, 8, 12, 13, 26, 27, 44, 45, 64, 66, 74

- Fibronectin assembly, 13, 25, 44  
 Fibrosis, 3, 9, 12, 14, 16, 29, 36–40, 54–56, 79–85, 90–92, 100, 102–109, 115–119, 121, 126, 128, 131, 139, 141, 146, 195–200, 207, 208, V  
 Filamin-A (FLNA), 187, 188  
 Fracture, 10, 49–57, 69, 166, 209
- G**  
 $\gamma$ -glutamyl-carboxylase, 14  
 Gastric cancer, 126, 128  
 Geno-endo-phenotype, 150–152  
 Gingiva, 64, 69, 74–76  
 Glaucoma, 114, 118  
 Glioma, 10, 11, 126, 127, 172, 199, 207  
 Grave prognosis, 80
- H**  
 Heart failure (HF), 36, 37, 39, 40, 178, 186  
 Heart regeneration, 16  
 Hematopoietic system, 167–169  
 Heparin-binding site, 11, 13  
 Human dental pulp, 74–76  
 Human periodontal ligament, 11, 74, 75, 166
- I**  
 Idiopathic pulmonary fibrosis (IPF), 9, 79–85  
 Integrin signaling, 8, 13, 104, 109, 140, 163–173, 186, 188  
 Interleukin (IL-13), 3, 11, 13, 16, 80, 81, 91, 96, 103, 104, 116, 119–121, 140, 145–149, 152–154, 156, 208, 209  
 Interleukin (IL-4), 3, 11, 13, 80, 81, 90, 91, 96, 103, 106, 116, 118, 121, 140, 145–147, 149, 152, 154, 156, 208, 209
- K**  
 Kidney, 15, 90, 99–109  
 Kidney disease, 15, 100, 102–109
- L**  
 Lebrikizumab, 148, 156, 208  
 Leukemia, 15, 126, 128–130, 132, 172, 173  
 Liver cancer, 126, 128  
 Liver fibrosis, 128, 139, 208  
 Lung cancer, 9, 12, 126, 128  
 Lysyl oxidase (LOX), 4, 12, 13, 24, 27, 29, 44, 46, 65, 100, 106, 107, 186
- M**  
 M2 macrophages, 11, 96, 115, 116  
 Macular degeneration, 114, 117, 118, 208  
 Mammalian target of rapamycin (mTOR), 15, 69, 104–105, 186  
 Matricellular protein (MPs), 3, 11, 14, 15, 24, 26, 28, 36–40, 50, 52, 54, 63, 69, 73, 74, 76, 80–83, 90, 91, 93, 95, 99, 101, 103, 114, 117, 118, 126, 145, 165, 178  
 Mechanical loading, 51, 67–68, 165, 166  
 Mechanical regulation, 28, 76  
 Mechanical stress, 3, 15, 16, 44–46, 52, 65, 67, 76, 100, 166, 209  
 Melanoma, 95, 129, 131, 208  
 Mesenchymal stem cell (MSC), 15, 46, 66, 69, 74, 165–167, 172  
 Molecular imaging, 198–200  
 Monitoring marker, 155, 156  
 Multimerization, 13, 14, 23–26  
 Muscular dystrophy (MD), 141  
 Myocardial infarction (MI), 3, 8, 9, 12, 14, 16, 36–40, 44, 100, 140, 208  
 Myofibroblasts, 4, 8, 16, 35–40, 80–82, 91, 92, 105, 106, 117, 126–128, 132, 139, 186
- N**  
 Neural stem cells, 140, 169–171, 198
- O**  
 Omalizumab, 153, 155, 156  
 Osteoporosis, 209
- P**  
 Pak, 186  
 Pancreatic cancer, 126, 127, 132  
 Periodontal ligament (PDL), 3, 9–12, 15, 28, 45, 46, 50, 52, 54, 63–70, 73–76, 90, 100, 165, 166, 196  
 Periodontal tissue regeneration, 63–70  
 Periodontium, 54, 63, 64, 67–70, 74, 76  
 Periosteal cell (PCs), 15, 46, 50, 52–55, 57  
 Periosteum, 3, 10, 15, 43–46, 49–58, 63, 66, 90, 100, 166, 196  
 Periostin antibody, 83, 101, 140, 208  
 Periostin functions, 3, 11, 13, 14, 16, 23–29, 44, 46, 58, 133, 183, 207, 208  
 Periostin genes, 7–16, 27, 43, 82, 140, 183, 184  
 Periostin-targeting ribonucleic acid drug, 120  
 Peripheral blood, 11, 130, 168, 196–198, 200  
 Perivascular niche, 11, 129–131  
 Polycystic kidney disease (PKD), 100, 102–109  
 Premetastatic niche, 129–131  
 Proliferative vitreoretinopathy (PVR), 114, 116, 117, 208  
 Proteinase digestion, 12, 13  
 Protein expression, 7–16, 57, 128, 178, 179, 184  
 Proteoglycan, 28, 91, 170, 183, 185  
 Pterygia, 114, 118
- R**  
 Remodeling, 15, 29, 35–40, 44, 50, 51, 63, 65–69, 73, 76, 90–96, 106, 109, 114, 119, 121, 126, 132, 133, 145, 146, 149, 155, 157, 165, 180, 183, 185–189, 198, 200  
 Renal development, 101, 109

Retinal neovascularization, 9, 114, 120, 207  
Rhinosinusitis, 139–141, 152, 153  
RNA interference (RNAi), 120, 121, 207

**S**

Scaffold, 4, 13, 23–29, 45, 69, 91, 100, 105, 133, 209  
Scar tissue formation, 90–92  
Scleroderma, 80, 81, 90, 92–93, 208  
Serum periostin, 83, 93, 96, 119, 127, 128, 132, 140, 146–157, 197, 198, 209  
Skeletal stem cell (SSCs), 15, 46, 49–52, 54–58  
Sputum periostin, 146, 148, 156, 157  
Stemness, 10, 14–15, 46, 58, 167–170, 173, v  
Steroid treatment, 150, 154–156  
Stroke, 3, 139–141, 208

**T**

Tenascin, 3, 4, 8, 11–13, 24, 26–28, 44, 45, 65, 66, 90–92, 100, 117, 133, 141, 165, 170, 196, 199–200  
Tenascin-C, 3, 4, 8, 11–13, 24, 27, 28, 44, 45, 65, 66, 90, 91, 100, 117, 165, 170, 196, 199–200  
TGF- $\beta$ -inducible gene, 11  
Therapeutic target, 16, 27, 85, 101, 105, 117, 121, 133, 208

Transactivator, 10

Tumor, 3, 9, 11, 12, 26–28, 46, 50, 69, 90, 95, 96, 100, 114, 125–133, 140, 167, 171–173, 195–200, 208  
Tumor growth-supportive microenvironment, 129, 132  
Tumor immunosuppressive microenvironment, 131–132  
Tumor microenvironment, 27, 28, 95, 96, 100, 126, 129–133, 196, 199, 200  
Type-2 airway inflammation, 145–146, 148, 157  
Type-2 biomarker, 149–150, 155, 157

**U**

Uterine fibroid, 140, 141

**V**

Valvuloseptal morphogenesis, 179–189  
Vascular adventitia, 38  
Vernal keratoconjunctivitis (VKC), 119  
Vertebral periostin gene, 9–10

**W**

Wound healing, 12, 15, 27, 36, 37, 39, 40, 80, 81, 85, 90–92, 114, 116, 186, 197